The COOPerative Establishment for Necessary Investigation in Clinical Outcome After Stenting (COPERNICOS)
Randomized Comparison of Outcome of Stenting in Unselected Patients in Everyday Clinical Practice
The superiority of a percutaneous coronary intervention (PCI) by one stent over another in terms of clinical outcome is usually documented in large randomized controlled trials (RCT). Although generated from selected study populations these data form the basis for evidence based practice (EBP) in the entire population of patients considered for coronary intervention. An inherent limitation of this approach is that study populations differ significantly from all comers in terms of patient characteristics and prognosis undermining the foundation for extrapolation of trial results to all comers. Furthermore, other trials are based on a "one-fits-all" concept, while the benefits of an "individual-tailored" approach that might be superior, is not investigated.
The Purpose of the current study is to
- Compare clinical outcome between several CE marked drug eluting stents
- Compare clinical outcome between several CE marked bare metal stents
- Compare clinical outcome in all comers with that of the selected study population of RCT's
- Evolve methods to compare clinical outcomes between the generalized "one-fits-all" versus the individualized or "individual-tailored" stent selection approaches
The Method employed is
- All comer PCI registry - single centre
- Randomisation of all eligible patients within the registry to one of several study stent
- Quality assurance in non-randomized population within the registry by periodical alternating the institutional standard stent
- Continuous follow up of all patients included the registry by means of systematic event detection and classification by an independent safety and end point committee
- Assessment of effects on quality of life by heart and health questionnaires
Outcome Measures
Primary endpoints:
- Composite of cardiac death, acute myocardial infraction and target vessel revascularisation
- Stent thrombosis
- A specifically developed Treatment Failure Rate classification
Secondary outcome measures include each of the above, target lesion revascularisation and total death analyzed in a hierarchical fashion at 2, 3, 4 and 5 years.
Tertiary outcome measure is self reported quality of life based on health questionnaires on general health and cardiac symptoms.
Power Calculations An event rate of 20% within 5 years, a relative difference of 25% (an absolute difference of 5%), P< 5%, Power > 80% => 900 patients in each of two treatment arms.
Prespecified Analysis include
- The MACE rates between stent types
- The Stent thrombosis rates between stent types
- The Treatment failure rates between stent types
- The randomized population versus non-randomized population
- The individualized versus the generalized Population
- QOL between stent types
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
All MACE and stent thromboses are adjudicated by an independent end point and safety committee chaired by Jørgen Jeppesen known from the very same task he executed in the SORT OUT II.
Further question may be answered by the four key investigators:
Steen Carstensen, Anders Galløe, Ole Havndrup, Lars Kjøller-Hansen
Studietype
Registrering (Forventet)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Roskilde, Danmark, 4000
- Roskilde County Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- to enter COPERNICOS registry for quality assessment: Each and every patient assigned to percutaneous coronary intervention will be included.
- to enter COPERNICOS randomization: If the patient fulfil the Helsinki declaration and have a Danish personal security identification number they are asked to give written informed consent to participate in the randomized study arms.
Exclusion Criteria to randomization:
- unconscious patients
- residents in other countries thereby escaping event detection
- patients unable to understand the rationale of the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Study group two
Endeavor resolute drug eluting stent
|
Biomatrix drug eluting stent
Andre navn:
|
|
Aktiv komparator: Study group three
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Andre navn:
|
|
Aktiv komparator: Study group four
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Andre navn:
|
|
Aktiv komparator: Study group five
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Andre navn:
|
|
Aktiv komparator: Study group one
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
MACE
Tidsramme: Five year
|
Major adverse cardiac events defined as a composite of cardiac death, acute myocardial infraction and target vessel revascularisation
|
Five year
|
|
Stent thromboses
Tidsramme: Five year
|
Definite, propable and possible
|
Five year
|
|
Treatment failure
Tidsramme: Five Years
|
A specifically developed Treatment Failure Classification
|
Five Years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Death of any cause
Tidsramme: One and five years
|
Ongoing quality assurance
|
One and five years
|
|
Self reported health questionnaires on general health and cardiac specific symptoms.
Tidsramme: One and five years
|
One and five years
|
|
|
Cardiac death
Tidsramme: One and five years
|
One and five years
|
|
|
Myocardial infarction
Tidsramme: One and five years
|
One and five years
|
|
|
Target lesion revascularisation
Tidsramme: One and five years
|
One and five years
|
|
|
Target vessel revascularisation
Tidsramme: One and five years
|
One and five years
|
|
|
Stent thrombosis
Tidsramme: One and five years
|
One and five years
|
|
|
Treatment Failure
Tidsramme: One and five years
|
One and five years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Anders M Galløe, Md.Ph.D., Zealand University Hospital
- Studiestol: Steen Carstensen, MD, Zealand University Hospital
- Studiestol: Ole Havndrup, MD, Zealand University Hospital
- Studiestol: Lars Kjøller-Hansen, MD, Zealand University Hospital
- Studieleder: Gunnar VH Jensen, MD, Zealand University Hospital
- Studieleder: Jørgen Jeppesen, MD, Glostrup University Hospital, Copenhagen
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- COPERNICOS
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .